{"component": "clause", "props": {"groups": [{"samples": [{"hash": "5FakLyB0nmv", "uri": "/contracts/5FakLyB0nmv#commercialization", "label": "Collaboration Agreement (Surface Oncology, Inc.)", "score": 29.2217655182, "published": true}, {"hash": "a77nconioih", "uri": "/contracts/a77nconioih#commercialization", "label": "Collaboration Agreement (Surface Oncology, Inc.)", "score": 29.1724853516, "published": true}, {"hash": "6quj7ED1kuV", "uri": "/contracts/6quj7ED1kuV#commercialization", "label": "Collaboration Agreement (Surface Oncology, Inc.)", "score": 28.8767967224, "published": true}], "snippet_links": [{"key": "determine-whether", "type": "clause", "offset": [33, 50]}, {"key": "to-manufacture", "type": "definition", "offset": [65, 79]}, {"key": "regional-licensed-products", "type": "clause", "offset": [113, 139]}, {"key": "such-determination", "type": "definition", "offset": [284, 302]}, {"key": "notice-to", "type": "definition", "offset": [314, 323]}, {"key": "initiation-of-the", "type": "clause", "offset": [346, 363]}, {"key": "phase-3-study", "type": "definition", "offset": [370, 383]}, {"key": "this-exhibit", "type": "definition", "offset": [430, 442]}, {"key": "replaced-with", "type": "clause", "offset": [460, 473]}, {"key": "the-secretary", "type": "clause", "offset": [549, 562]}, {"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [566, 604]}, {"key": "confidential-treatment", "type": "definition", "offset": [643, 665]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [666, 682]}, {"key": "securities-act-of-1933", "type": "clause", "offset": [709, 731]}, {"key": "as-amended", "type": "definition", "offset": [733, 743]}, {"key": "in-accordance-with", "type": "definition", "offset": [910, 928]}, {"key": "the-foregoing", "type": "definition", "offset": [929, 942]}, {"key": "receipt-of", "type": "clause", "offset": [1029, 1039]}, {"key": "commercial-manufacturing", "type": "clause", "offset": [1103, 1127]}, {"key": "third-party-contract", "type": "definition", "offset": [1168, 1188]}, {"key": "to-provide", "type": "clause", "offset": [1257, 1267]}, {"key": "commercial-supply", "type": "definition", "offset": [1273, 1290]}, {"key": "transfer-to-a-third-party", "type": "clause", "offset": [1448, 1473]}, {"key": "provided-that", "type": "definition", "offset": [1652, 1665]}, {"key": "by-novartis", "type": "clause", "offset": [1720, 1731]}, {"key": "cost-of", "type": "definition", "offset": [1808, 1815]}, {"key": "in-the-case", "type": "clause", "offset": [1872, 1883]}, {"key": "request-for", "type": "definition", "offset": [1981, 1992]}, {"key": "responsible-for", "type": "clause", "offset": [2279, 2294]}, {"key": "the-technology", "type": "clause", "offset": [2398, 2412]}, {"key": "terms-of-supply", "type": "definition", "offset": [2703, 2718]}, {"key": "supply-agreement", "type": "clause", "offset": [2938, 2954]}], "snippet": "Novartis shall have the right to determine whether it is willing to Manufacture Regional Antibody Candidates and Regional Licensed Products for use in Commercialization of such Regional Antibody Candidates and Regional Licensed Products in the Surface Territory and shall communicate such determination by written notice to Surface no later than Initiation of the first Phase 3 Study. If Novartis CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH \u201c[***]\u201d. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. notifies Surface that it is willing to Manufacture Regional Antibody Candidates and Regional Licensed Products for use in Commercialization in the Surface Territory in accordance with the foregoing, then, Surface may elect, by written notice to Novartis no later than [***] after its receipt of such notice from Novartis whether to utilize Novartis for such Commercial Manufacturing in the Surface Territory or to retain a Third Party contract manufacturer(s) for such purpose. If either Novartis is not willing to provide such Commercial supply (a \u201cNovartis Election\u201d) or Surface elects not to utilize Novartis for such Commercial supply (a \u201cSurface Election\u201d), then Novartis shall effect a technology transfer to a Third Party contract manufacturer(s) to enable such Third Party to provide Commercial supply of Regional Antibody Candidates and Regional Licensed Products for use in the Surface Territory, provided that such Third Party contract manufacturer(s) is approved by Novartis, such approval not to be unreasonably withheld, conditioned or delayed. The cost of such technology transfer shall be borne by (a) Novartis in the case of a Novartis Election; and (b) Surface in the case of either (i) a Surface Election or (ii) any request for a second technology transfer, whether in the case of a Novartis Election or Surface Election; provided, however that Surface may not require of Novartis more than [***] such transfers for any Regional Licensed Product. Further, in the case of a Novartis Election, Novartis shall remain responsible for Manufacturing Commercial supply for use in the Surface Territory until the earlier of (x) such time as the technology transfer is completed or (y) [***] If Novartis is willing to Manufacture Regional Antibody Candidates and Regional Licensed Products for use in Commercialization in the Surface Territory and Surface elects to utilize Novartis for such Commercial Manufacturing in the Surface Territory, the terms of supply of such Regional Antibody Candidates and Regional Licensed Products for use in Commercialization of such Regional Antibody Candidates and Regional Licensed Products in the Surface Territory will be set forth in the RLP Supply Agreement.", "size": 34, "hash": "73aba215bb476104fae45d324294df85", "id": 2}, {"samples": [{"hash": "FqP4X806I2", "uri": "/contracts/FqP4X806I2#commercialization", "label": "Exclusive Channel Collaboration Agreement (Castle Creek Biosciences, Inc.)", "score": 32.5373039246, "published": true}, {"hash": "21YulHc3wiS", "uri": "/contracts/21YulHc3wiS#commercialization", "label": "Exclusive Channel Collaboration Agreement (Castle Creek Biosciences, Inc.)", "score": 32.4031486511, "published": true}, {"hash": "8i1U69YSon0", "uri": "/contracts/8i1U69YSon0#commercialization", "label": "Exclusive Channel Collaboration Agreement (Fibrocell Science, Inc.)", "score": 27.0068454742, "published": true}], "snippet_links": [{"key": "right-to-develop", "type": "clause", "offset": [24, 40]}, {"key": "reverted-products", "type": "definition", "offset": [63, 80]}, {"key": "third-parties", "type": "clause", "offset": [108, 121]}, {"key": "obligation-to", "type": "clause", "offset": [157, 170]}, {"key": "in-connection-with", "type": "clause", "offset": [207, 225]}], "snippet": "Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.", "size": 42, "hash": "fdf25d2c49bdaa1af60dd0a8f396c0f5", "id": 1}, {"samples": [{"hash": "9UKSM6MoXOX", "uri": "/contracts/9UKSM6MoXOX#commercialization", "label": "License Agreement", "score": 33.493347168, "published": true}, {"hash": "8BTiZcAhKvm", "uri": "/contracts/8BTiZcAhKvm#commercialization", "label": "License Agreement", "score": 33.2059211731, "published": true}, {"hash": "8Dy7Yg2U5Ry", "uri": "/contracts/8Dy7Yg2U5Ry#commercialization", "label": "License Agreement", "score": 33.1785469055, "published": true}], "snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [0, 14]}, {"key": "strict-adherence", "type": "clause", "offset": [71, 87]}, {"key": "legal-requirements", "type": "definition", "offset": [121, 139]}, {"key": "in-the-territory", "type": "clause", "offset": [140, 156]}, {"key": "to-the-extent", "type": "clause", "offset": [168, 181]}, {"key": "consistent-with", "type": "definition", "offset": [203, 218]}, {"key": "applicable-regulatory-approvals", "type": "definition", "offset": [224, 255]}, {"key": "without-limitation", "type": "clause", "offset": [268, 286]}, {"key": "key-approvals", "type": "clause", "offset": [288, 301]}, {"key": "in-no-event-shall", "type": "clause", "offset": [304, 321]}, {"key": "directly-or-indirectly", "type": "clause", "offset": [332, 354]}, {"key": "offer-for-sale", "type": "clause", "offset": [373, 387]}, {"key": "distribute-the", "type": "clause", "offset": [415, 429]}, {"key": "outside-of-the-field", "type": "clause", "offset": [459, 479]}, {"key": "commercialization-of-the-licensed-product", "type": "clause", "offset": [539, 580]}, {"key": "good-will", "type": "clause", "offset": [635, 644]}], "snippet": "Licensee shall promote, Commercialize and sell the Licensed Product in strict adherence to regulatory, professional, and legal requirements in the Territory and solely to the extent permitted under, and consistent with, all applicable regulatory approvals (including, without limitation, Key Approvals). In no event shall Licensee, directly or indirectly, promote, market, offer for sale, sell, donate or otherwise distribute the Licensed Product for any use outside of the Field or otherwise perform any off-label promotion, marketing or Commercialization of the Licensed Product. Licensee shall do nothing which would jeopardize the good will or reputation of MPP or Pfizer or the reputation of the Compound, Product and/or Licensed Product.", "size": 31, "hash": "27cf9b69f089244e8f6987eeff7d67a4", "id": 3}, {"samples": [{"hash": "iNJ6ONKIKi6", "uri": "/contracts/iNJ6ONKIKi6#commercialization", "label": "Executive Employment Agreement (InMed Pharmaceuticals Inc.)", "score": 35.1054077148, "published": true}, {"hash": "c5BxE6dgEtQ", "uri": "/contracts/c5BxE6dgEtQ#commercialization", "label": "Executive Employment Agreement (InMed Pharmaceuticals Inc.)", "score": 33.5475692749, "published": true}, {"hash": "jiTGod40oHF", "uri": "/contracts/jiTGod40oHF#commercialization", "label": "Executive Employment Agreement (InMed Pharmaceuticals Inc.)", "score": 32.5290908813, "published": true}], "snippet_links": [{"key": "the-executive", "type": "clause", "offset": [0, 13]}, {"key": "the-decision", "type": "clause", "offset": [31, 43]}, {"key": "to-commercialize", "type": "definition", "offset": [59, 75]}, {"key": "work-product", "type": "definition", "offset": [90, 102]}, {"key": "sole-discretion", "type": "definition", "offset": [127, 142]}, {"key": "for-the-company", "type": "clause", "offset": [147, 162]}, {"key": "sole-benefit", "type": "definition", "offset": [165, 177]}, {"key": "no-royalty", "type": "clause", "offset": [187, 197]}, {"key": "other-consideration", "type": "definition", "offset": [201, 220]}, {"key": "payable-to", "type": "definition", "offset": [236, 246]}, {"key": "of-the-company", "type": "clause", "offset": [263, 277]}], "snippet": "The Executive understands that the decision whether or not to commercialize or market any Work Product is within the Company\u2019s sole discretion and for the Company\u2019s sole benefit and that no royalty or other consideration will be due or payable to him as a result of the Company\u2019s efforts to commercialize or market any such Work Product.", "size": 9, "hash": "0f907193e94c04b15933aace49de8324", "id": 7}, {"samples": [{"hash": "kb2KwWnhafZ", "uri": "/contracts/kb2KwWnhafZ#commercialization", "label": "Asset Purchase Agreement (Mereo Biopharma Group PLC)", "score": 30.0650234222, "published": true}, {"hash": "iD9GfsDaOI8", "uri": "/contracts/iD9GfsDaOI8#commercialization", "label": "Asset Purchase Agreement (Mereo Biopharma Group PLC)", "score": 30.0650234222, "published": true}, {"hash": "1ZGQlyyZwNY", "uri": "/contracts/1ZGQlyyZwNY#commercialization", "label": "Asset Purchase Agreement (Mereo Biopharma Group PLC)", "score": 30.0650234222, "published": true}], "snippet_links": [{"key": "responsibility-for", "type": "clause", "offset": [22, 40]}, {"key": "commercialization-of-the-products", "type": "clause", "offset": [71, 104]}, {"key": "planning-and-implementation", "type": "clause", "offset": [116, 143]}, {"key": "booking-of-sales", "type": "clause", "offset": [159, 175]}], "snippet": "Sellers shall have no responsibility for any aspects of Development or Commercialization of the Products, including planning and implementation, distribution, booking of sales, pricing or reimbursement.", "size": 9, "hash": "06f506fc4da21a5d2d747a05107bd748", "id": 6}, {"samples": [{"hash": "iWmHD8wJPGR", "uri": "/contracts/iWmHD8wJPGR#commercialization", "label": "License Agreement (VIASPACE Inc.)", "score": 21.0, "published": true}, {"hash": "8PmmWdxi5Ir", "uri": "/contracts/8PmmWdxi5Ir#commercialization", "label": "License Agreement (VIASPACE Inc.)", "score": 21.0, "published": true}], "snippet_links": [{"key": "licensee-agrees-to", "type": "clause", "offset": [0, 18]}, {"key": "reasonable-efforts", "type": "definition", "offset": [23, 41]}, {"key": "licensed-products", "type": "clause", "offset": [68, 85]}, {"key": "in-the-field", "type": "clause", "offset": [86, 98]}, {"key": "as-soon-as-practicable", "type": "definition", "offset": [99, 121]}, {"key": "licensee-shall", "type": "clause", "offset": [123, 137]}, {"key": "section-61", "type": "clause", "offset": [193, 204]}, {"key": "marketing-program", "type": "definition", "offset": [268, 285]}, {"key": "commercial-production", "type": "definition", "offset": [313, 334]}, {"key": "of-licensee", "type": "clause", "offset": [389, 400]}, {"key": "purpose-of", "type": "clause", "offset": [483, 493]}, {"key": "compliance-with", "type": "definition", "offset": [517, 532]}], "snippet": "Licensee agrees to use reasonable efforts to commercially introduce Licensed Products in the Field as soon as practicable. Licensee shall be deemed to have satisfied its obligations under this Section 6.1 if Licensee has an ongoing and active research, development or marketing program, directed primarily toward commercial production and use of one or more Licensed Products. Any efforts of Licensee\u2019s Affiliates or sublicensees shall be considered efforts of Licensee for the sole purpose of determining Licensee\u2019s compliance with its obligation under this Section 6.1.", "size": 10, "hash": "d303e1d9c8e322bc77b33d6184adca87", "id": 5}, {"samples": [{"hash": "aqqfj3FR3dp", "uri": "/contracts/aqqfj3FR3dp#commercialization", "label": "License and Commercialization Agreement (Bellerophon Therapeutics, Inc.)", "score": 26.2429847717, "published": true}, {"hash": "642nEY2fakH", "uri": "/contracts/642nEY2fakH#commercialization", "label": "License and Commercialization Agreement (BioLineRx Ltd.)", "score": 26.22108078, "published": true}, {"hash": "eqgtMpj78Xc", "uri": "/contracts/eqgtMpj78Xc#commercialization", "label": "License and Commercialization Agreement (Bellerophon Therapeutics LLC)", "score": 26.032169342, "published": true}], "snippet_links": [{"key": "responsible-for", "type": "clause", "offset": [23, 38]}, {"key": "commercialization-of-products", "type": "clause", "offset": [98, 127]}, {"key": "in-the-field", "type": "clause", "offset": [128, 140]}, {"key": "in-the-territory", "type": "clause", "offset": [141, 157]}, {"key": "contracting-with", "type": "clause", "offset": [173, 189]}, {"key": "booking-sales", "type": "clause", "offset": [204, 217]}, {"key": "conditions-under-which", "type": "clause", "offset": [255, 277]}, {"key": "sold-to", "type": "clause", "offset": [295, 302]}, {"key": "managed-care", "type": "definition", "offset": [334, 346]}, {"key": "subject-to-section", "type": "clause", "offset": [362, 380]}, {"key": "between-the-parties", "type": "clause", "offset": [458, 477]}, {"key": "all-costs", "type": "definition", "offset": [497, 506]}, {"key": "from-time-to-time", "type": "clause", "offset": [561, 578]}, {"key": "commercialization-plan", "type": "clause", "offset": [595, 617]}, {"key": "plans-for", "type": "clause", "offset": [670, 679]}, {"key": "major-market", "type": "definition", "offset": [712, 724]}, {"key": "initial-commercialization", "type": "definition", "offset": [844, 869]}, {"key": "binding-obligation", "type": "clause", "offset": [965, 983]}, {"key": "by-ikaria", "type": "clause", "offset": [1030, 1039]}, {"key": "notice-of-any", "type": "clause", "offset": [1125, 1138]}, {"key": "change-to", "type": "clause", "offset": [1157, 1166]}, {"key": "most-recent", "type": "definition", "offset": [1183, 1194]}], "snippet": "Ikaria shall be solely responsible for conducting, itself or through Affiliates or Licensees, the Commercialization of Products in the Field in the Territory, including (a) contracting with customers and booking sales, (b) setting the price and terms and conditions under which a Product may be sold to customers, and (c) handling of managed care accounts, and, subject to Section 1.29, Section 4.2(b), Section 5.2(d), Section 5.3(e) and Section 10.1(b), as between the Parties, Ikaria shall bear all costs associated therewith. Ikaria shall produce and update from time to time a comprehensive Commercialization plan (the \u201cCommercialization Plan\u201d), which shall include plans for Commercializing Product in each major market in which Ikaria does not then have a presence. The Commercialization Plan shall include a preliminary timeline for the initial Commercialization of Products, which is intended as a planning and informational tool and shall not constitute a binding obligation on Ikaria, and shall be subject to adjustment by Ikaria from time to time, provided, that, Ikaria shall provide BioLineRx with prior written notice of any material proposed change to a timeline. The most recent preliminary Commercialization Plan is attached hereto as Schedule 3.7.", "size": 8, "hash": "5dc95560ec50f0d56a2c1a7e4ce5f4aa", "id": 10}, {"samples": [{"hash": "dssH93lEYje", "uri": "/contracts/dssH93lEYje#commercialization", "label": "License and Development Agreement (Exicure, Inc.)", "score": 30.3470230103, "published": true}], "snippet_links": [{"key": "right-to-commercialize", "type": "clause", "offset": [33, 55]}, {"key": "sole-discretion", "type": "definition", "offset": [160, 175]}, {"key": "section-97", "type": "clause", "offset": [188, 199]}, {"key": "commercially-reasonable-efforts-to-commercialize", "type": "clause", "offset": [339, 387]}, {"key": "primary-indication", "type": "definition", "offset": [430, 448]}, {"key": "additional-indication", "type": "definition", "offset": [496, 517]}, {"key": "section-24", "type": "definition", "offset": [545, 556]}, {"key": "in-the-territory", "type": "clause", "offset": [573, 589]}, {"key": "in-the-field", "type": "clause", "offset": [590, 602]}, {"key": "reasonably-believes", "type": "definition", "offset": [615, 634]}, {"key": "material-breach-of-this-agreement", "type": "clause", "offset": [871, 904]}, {"key": "subject-to-and-in-accordance-with", "type": "clause", "offset": [906, 939]}, {"key": "termination-provisions", "type": "clause", "offset": [944, 966]}, {"key": "section-94", "type": "clause", "offset": [970, 981]}, {"key": "article-10", "type": "definition", "offset": [1023, 1033]}, {"key": "determination-of", "type": "clause", "offset": [1050, 1066]}, {"key": "an-uncured-material-breach", "type": "clause", "offset": [1067, 1093]}, {"key": "the-provisions-of-section", "type": "clause", "offset": [1100, 1125]}, {"key": "right-to-terminate-this-agreement", "type": "clause", "offset": [1169, 1202]}, {"key": "notice-to", "type": "definition", "offset": [1226, 1235]}, {"key": "with-respect-to", "type": "clause", "offset": [1246, 1261]}, {"key": "granted-to", "type": "clause", "offset": [1281, 1291]}, {"key": "article-2", "type": "clause", "offset": [1307, 1316]}, {"key": "associated-with", "type": "definition", "offset": [1422, 1437]}, {"key": "commercialization-of-licensed-products", "type": "clause", "offset": [1438, 1476]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [1491, 1520]}, {"key": "strategic-matters", "type": "clause", "offset": [1581, 1598]}, {"key": "in-particular", "type": "clause", "offset": [1604, 1617]}, {"key": "related-to", "type": "definition", "offset": [1626, 1636]}, {"key": "set-out", "type": "definition", "offset": [1670, 1677]}, {"key": "guiding-principles", "type": "definition", "offset": [1685, 1703]}, {"key": "in-full-force", "type": "definition", "offset": [1813, 1826]}, {"key": "in-effect", "type": "definition", "offset": [1827, 1836]}], "snippet": "Dermelix will have the exclusive right to Commercialize Licensed Products itself or through one or more Affiliates or Sublicensees selected by Dermelix, in its sole discretion. Subject to Section 9.7, Dermelix (itself or through one or more Affiliates or Sublicensees selected by Dermelix, in its sole discretion) shall be required to use Commercially Reasonable Efforts to Commercialize at least one (1) Licensed Product for the Primary Indication and at least one (1) Licensed Product for each Additional Indication selected by Dermelix under Section 2.4 or Section 2.5, in the Territory in the Field. If Exicure reasonably believes that Dermelix (or its Affiliate or Sublicensee, as applicable) has failed to use Commercially Reasonable Efforts to Commercialize Licensed Products as described in this paragraph, then such failure, if not cured, shall be grounds for a material breach of this Agreement, subject to and in accordance with the termination provisions of Section 9.4 and the dispute resolution provisions of Article 10. Upon any final determination of an uncured material breach under the provisions of Section 9.4 and Article 10, Exicure shall have the right to terminate this Agreement immediately on written notice to Dermelix, with respect to the license rights granted to Dermelix under Article 2 with respect to the Indication(s) to which the breach applies. Dermelix will bear all costs and expenses associated with Commercialization of Licensed Products in the Field. Notwithstanding the foregoing, Dermelix will inform and consult with Exicure on important strategic matters, and in particular matters related to pricing of Licensed Products, as set out in the Guiding Principles. Notwithstanding the foregoing, this Agreement and the license rights granted under Article 2 shall continue in full force in effect with respect to all Indications that are not subject to such termination.", "size": 9, "hash": "456ec2f648faea4ae7860f296dbcf36c", "id": 9}, {"samples": [{"hash": "e7Z7WxhFecw", "uri": "/contracts/e7Z7WxhFecw#commercialization", "label": "Development and Commercialization Agreement (Mesoblast LTD)", "score": 26.7193698883, "published": true}, {"hash": "hgoBviDMJyR", "uri": "/contracts/hgoBviDMJyR#commercialization", "label": "Development and Commercialization Agreement (Mesoblast LTD)", "score": 25.9390830994, "published": true}, {"hash": "8Y3QglFoAQk", "uri": "/contracts/8Y3QglFoAQk#commercialization", "label": "Development and Commercialization Agreement (Cephalon Inc)", "score": 22.338809967, "published": true}], "snippet_links": [{"key": "supply-of-products", "type": "clause", "offset": [29, 47]}, {"key": "the-agreement", "type": "clause", "offset": [64, 77]}, {"key": "sale-of", "type": "clause", "offset": [119, 126]}, {"key": "in-the-territory", "type": "clause", "offset": [139, 155]}, {"key": "marketing-partners", "type": "definition", "offset": [190, 208]}, {"key": "the-products", "type": "clause", "offset": [238, 250]}, {"key": "marketing-approval", "type": "definition", "offset": [294, 312]}, {"key": "in-accordance-with", "type": "definition", "offset": [341, 359]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [364, 402]}, {"key": "in-writing", "type": "definition", "offset": [457, 467]}, {"key": "in-no-event", "type": "clause", "offset": [573, 584]}, {"key": "date-of", "type": "clause", "offset": [643, 650]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [655, 684]}, {"key": "provided-that", "type": "definition", "offset": [732, 745]}, {"key": "notice-by", "type": "clause", "offset": [892, 901]}, {"key": "other-provision-of-this-agreement", "type": "clause", "offset": [997, 1030]}, {"key": "with-respect-to", "type": "clause", "offset": [1123, 1138]}, {"key": "territory-shall", "type": "definition", "offset": [1159, 1174]}, {"key": "without-limiting-the-foregoing", "type": "clause", "offset": [1197, 1227]}, {"key": "right-to", "type": "definition", "offset": [1255, 1263]}, {"key": "products-sold", "type": "clause", "offset": [1376, 1389]}, {"key": "subject-to", "type": "definition", "offset": [1468, 1478]}, {"key": "payment-obligations", "type": "clause", "offset": [1490, 1509]}, {"key": "article-vi", "type": "definition", "offset": [1516, 1526]}, {"key": "within-thirty", "type": "clause", "offset": [1534, 1547]}, {"key": "expiration-of-the", "type": "clause", "offset": [1561, 1578]}, {"key": "the-request", "type": "clause", "offset": [1618, 1629]}, {"key": "transfer-to", "type": "definition", "offset": [1645, 1656]}, {"key": "all-products", "type": "clause", "offset": [1685, 1697]}, {"key": "bmt-mpcs", "type": "definition", "offset": [1702, 1710]}, {"key": "provisional-transfer-price", "type": "definition", "offset": [1735, 1761]}], "snippet": "To avoid a disruption in the supply of Products to patients, if the Agreement is terminated after the first commercial sale of any Product in the Territory, Cephalon, its Affiliates and its Marketing Partners shall continue to distribute the Products in each country of the Territory for which Marketing Approval therefor has been obtained, in accordance with the terms and conditions of this Agreement, until the date on which Angioblast notifies Cephalon in writing that Angioblast has secured an alternative distributor or licensee for the Products in such country, but in no event more for than twenty-four (24) months after the effective date of any termination of this Agreement, in whole or in part (the \u201cWind-down Period\u201d); provided that Cephalon, its Affiliates and its Marketing Partners shall cease such activities, or any portion thereof, in a given country upon sixty (60) days\u2019 notice by Angioblast requesting that such activities (or portion thereof) be ceased. Notwithstanding any other provision of this Agreement, during the Wind-down Period, Cephalon\u2019s and its Affiliates\u2019 and Marketing Partners\u2019 rights with respect to the Products in the Territory shall be non-exclusive and, without limiting the foregoing, Angioblast shall have the right to engage one or more other distributor(s) and/or licensee(s) of any Products in all or part of the Territory. Any Products sold or disposed by Cephalon in the Territory during the Wind-down Period shall be subject to applicable payment obligations under ARTICLE VI above. Within thirty (30) days of expiration of the Wind-down Period, Cephalon shall, upon the request of Angioblast, transfer to Angioblast or its designee, all Products and BMT MPCs in its inventory at the provisional transfer price therefor (as set forth in Paragraph 2(c) of Exhibit 6.3).", "size": 13, "hash": "e4775cac650d80a3e51a22434b965765", "id": 4}, {"samples": [{"hash": "cmdJaCd0fRf", "uri": "/contracts/cmdJaCd0fRf#commercialization", "label": "License and Technology Transfer Agreement", "score": 35.3032951355, "published": true}, {"hash": "bbQZHDvwYWR", "uri": "/contracts/bbQZHDvwYWR#commercialization", "label": "Sublicense and Technology Transfer Agreement", "score": 28.5770339966, "published": true}, {"hash": "8D30dcd5n7u", "uri": "/contracts/8D30dcd5n7u#commercialization", "label": "Sublicense and Technology Transfer Agreement", "score": 26.647190094, "published": true}], "snippet_links": [{"key": "the-sublicensee", "type": "clause", "offset": [4, 19]}, {"key": "be-responsible", "type": "clause", "offset": [25, 39]}, {"key": "conduct-of", "type": "clause", "offset": [69, 79]}, {"key": "relating-to", "type": "definition", "offset": [95, 106]}, {"key": "commercialization-of-the-licensed-products", "type": "clause", "offset": [111, 153]}, {"key": "in-the-territory", "type": "clause", "offset": [154, 170]}, {"key": "sublicense-agreement", "type": "clause", "offset": [243, 263]}, {"key": "to-the-extent", "type": "clause", "offset": [280, 293]}, {"key": "prohibited-by-law", "type": "clause", "offset": [298, 315]}, {"key": "a-notice", "type": "definition", "offset": [327, 335]}, {"key": "markings-and-notices", "type": "clause", "offset": [423, 443]}, {"key": "required-by", "type": "definition", "offset": [454, 465]}, {"key": "applicable-law", "type": "definition", "offset": [466, 480]}, {"key": "in-relation-to", "type": "clause", "offset": [492, 506]}, {"key": "other-intellectual-property", "type": "definition", "offset": [518, 545]}, {"key": "all-reasonable-efforts", "type": "clause", "offset": [576, 598]}, {"key": "to-provide", "type": "clause", "offset": [599, 609]}, {"key": "adequate-supply", "type": "definition", "offset": [613, 628]}, {"key": "provide-a", "type": "definition", "offset": [746, 755]}, {"key": "distribution-of", "type": "clause", "offset": [793, 808]}, {"key": "recognition-of", "type": "clause", "offset": [852, 866]}, {"key": "access-to-the", "type": "clause", "offset": [1004, 1017]}], "snippet": "(a) The Sublicensee will be responsible, at its own expense, for the conduct of all activities relating to the Commercialization of the Licensed Products in the Territory.\n(b) Each Licensed Product Commercialized by the Sublicensee under this Sublicense Agreement will be marked (to the extent not prohibited by law):\n(i) with a notice that such Licensed Product is sold under a license from BMS and MPP; and\n(ii) with all markings and notices as may be required by applicable law, including in relation to patent and other intellectual property.\n(c) The Sublicensee will use all reasonable efforts to provide an adequate supply of the Licensed Products (in all formulations and strengths) to meet the therapeutic needs in the Territory and will provide a strong supply network to support the distribution of the Licensed Products in the Territory. In recognition of the humanitarian objectives of this Sublicense Agreement, the Sublicensee also will use all reasonable efforts to promote the affordable access to the Licensed Products in the Territory.", "size": 9, "hash": "529c30776a90a2485a04820d959e0784", "id": 8}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ihpjb21tZXJjaWFsaXphdGlvbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "clause": {"children": [["general", "General"], ["diligence", "Diligence"], ["commercialization-reports", "Commercialization Reports"], ["commercialization-plan", "Commercialization Plan"], ["commercial-diligence", "Commercial Diligence"]], "title": "Commercialization", "parents": [["development-and-commercialization", "Development and Commercialization"], ["effect-of-termination", "Effect of Termination"], ["commercialization", "Commercialization"], ["term-termination", "Term Termination"], ["development-manufacture-and-registration", "Development Manufacture and Registration"]], "size": 2095, "id": "commercialization", "related": [["development-and-commercialization", "Development and Commercialization", "Development and <strong>Commercialization</strong>"], ["commercialization-license", "Commercialization License", "<strong>Commercialization</strong> License"], ["commercialization-plan", "Commercialization Plan", "<strong>Commercialization</strong> Plan"], ["development-activities", "Development Activities", "Development Activities"], ["licensed-product", "Licensed Product", "Licensed Product"]], "related_snippets": [], "updated": "2026-04-30T06:05:53+00:00"}, "json": true, "cursor": ""}}